IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
argenx reports Q3 2026 VYVGART sales of $1.7 billion, outlines pipeline timelinesOct 22Quarterly updateargenxefgartigimod alfa and hyaluronidase (human recombinant)
argenx to present Phase 3 ALKIVIA myositis data at ACR Convergence 2026Oct 19Publicationargenxefgartigimod
argenx reports positive Phase 3 ALKIVIA results for efgartigimod in autoimmune myositisAug 17Clinical readoutargenxefgartigimod
Halozyme posts record Q2 2026, raises full-year guidance on royalty growthAug 6Quarterly updateHalozyme Therapeutics